View clinical trials related to Hypergammaglobulinemia.
Filter by:This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with WaldenstrÓ§m's macroglobulinemia (WM). The study will evaluate this combination in two cohorts. Cohort A will comprise of ibrutinib naïve WM patients. Patients in this cohort may be treatment naïve or relapsed but who remain ibrutinib naïve. Cohort B will comprise of patients who are currently receiving ibrutinib but whose response to treatment has plateaued. In this cohort, daratumumab will be added on to ibrutinib in an attempt to deepen response.